Struggling British biotech firm Vernalis reports "striking" weight loss among patients taking its new obesity drug, "V24343".
posted by chuckdarwin on Sep 14, 2007 - 26 comments

"Well, a lot of people have said DEA is in the dark on these issues, but that is a little bit much." (.doc; long) Despite a power outage, an FDA-lead panel discusses how to manage abuse of the infamous opiod painkiller OxyContin. Purdue Pharma, its sole manufacturer, had tried to bring its more powerful successor Palladone (.pdf) to the market, before "dosage jump" issues lead to the drug being pulled by the FDA. Meanwhile, trucks loaded with $3mil dollars of "oxys" continue to get hijacked for a $15mil street turnover, despite GPS tracking and other high-tech security measures used for cigarette distribution. Doctors invariably shuffle pills sideways despite tamper-proof presciption pads (long). Purdue only stops selling more profitable and addictive double-doses of OxyContin after government pressure. On the level of the street, addicts who find themselves too tolerant to the drug find their needs more than adequately met when they can buy many more hits of heroin for the same cost. Philadelphia-based writer Jeff Deeney outlines some of these fascinating issues and more as he looks into how race, cost, manufacturing and distribution factors in OxyContin abuse invariably drive the addict to cheaper and more easily accessible heroin.
posted by Rothko on Feb 2, 2006 - 72 comments

How to think about prescription drugs. Malcolm Gladwell's latest piece in The New Yorker
The emphasis of the prescription-drug debate is all wrong. We've been focussed on the drug manufacturers. But decisions about prevalence, therapeutic mix, and intensity aren't made by the producers of drugs. They’re made by the consumers of drugs.
posted by trharlan on Oct 31, 2004 - 20 comments

Haunted by a truly global epidemic, perhaps it is time to consider the effects of globalization on the spread of diseases like AIDS. In addition to making it easier for disease to achieve global prevalence, global economics reduce funding for public health by placing treatment emphasis on those who can pay for their drugs, and, in the case of AIDS, may also encourage pharmaceutical companies to pursue expensive life-long 'treatments' rather than cures. Furthermore, younger, economically depressed members of the global economy are wholly dependent on the whim of richer nations for their well-being in the face of devastating epidemics. In this case, it seems that the global marketplace has failed to be the holy grail it is so often presented as.
posted by kaibutsu on Dec 1, 2003 - 17 comments

Inventing a new disease? Some experts are saying that the drug industry is trying lump women’s sexual problems under the term “female sexual dysfunction” to create a market for lucrative new Viagra-like drugs. A study in the Journal of the American Medical Association [abstract] found sexual dysfunction is more prevalent for women (43%) than men (31%), but the jury is still out.
posted by gottabefunky on Jan 3, 2003 - 54 comments